Figure 6.

The treating strategies for response group, alongside two selected patients’ evolutionary dynamics. (A) The dosing policies for patients in the response group. Each row denotes a responsive patient. The left and right bars present the IADT and IADT outcomes, respectively. (B) and (C) present the evolutionary dynamics of PSA and cancer cells under IADT and standard IADT in patient106, respectively. In Figure (B), there are 13 treatment cycles for 120 months (9 months per cycle in average), while in Figure (C), there are 2.5 cycles for 62 months (25 months per cycle in average).